These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Solriamfetol Titration & AdministRaTion (START) in Patients With Narcolepsy. Thorpy MJ, Hyman D, Parks GS, Chen A, Foley C, Baldys B, Ito D, Singh H. Clin Ther; 2022 Oct; 44(10):1356-1369. PubMed ID: 36171171 [Abstract] [Full Text] [Related]
23. Comparative Efficacy and Safety of Wakefulness-Promoting Agents for Excessive Daytime Sleepiness in Patients With Obstructive Sleep Apnea : A Systematic Review and Network Meta-analysis. Pitre T, Mah J, Roberts S, Desai K, Gu Y, Ryan C, Busse JW, Zeraatkar D. Ann Intern Med; 2023 May; 176(5):676-684. PubMed ID: 37155992 [Abstract] [Full Text] [Related]
29. A randomized study of solriamfetol for excessive sleepiness in narcolepsy. Thorpy MJ, Shapiro C, Mayer G, Corser BC, Emsellem H, Plazzi G, Chen D, Carter LP, Wang H, Lu Y, Black J, Dauvilliers Y. Ann Neurol; 2019 Mar; 85(3):359-370. PubMed ID: 30694576 [Abstract] [Full Text] [Related]
30. Modafinil improves daytime sleepiness in patients with mild to moderate obstructive sleep apnoea not using standard treatments: a randomised placebo-controlled crossover trial. Chapman JL, Kempler L, Chang CL, Williams SC, Sivam S, Wong KK, Yee BJ, Grunstein RR, Marshall NS. Thorax; 2014 Mar; 69(3):274-9. PubMed ID: 24287166 [Abstract] [Full Text] [Related]
34. Pitolisant for Daytime Sleepiness in Patients with Obstructive Sleep Apnea Who Refuse Continuous Positive Airway Pressure Treatment. A Randomized Trial. Dauvilliers Y, Verbraecken J, Partinen M, Hedner J, Saaresranta T, Georgiev O, Tiholov R, Lecomte I, Tamisier R, Lévy P, Scart-Gres C, Lecomte JM, Schwartz JC, Pépin JL, HAROSA II Study Group collaborators. Am J Respir Crit Care Med; 2020 May 01; 201(9):1135-1145. PubMed ID: 31917607 [Abstract] [Full Text] [Related]
35. Health-related impact of illness associated with excessive daytime sleepiness in patients with obstructive sleep apnea. Grandner MA, Min JS, Saad R, Leary EB, Eldemir L, Hyman D. Postgrad Med; 2023 Jun 01; 135(5):501-510. PubMed ID: 37129416 [Abstract] [Full Text] [Related]
37. Alertness and psychomotor performance effects of the histamine-3 inverse agonist MK-0249 in obstructive sleep apnea patients on continuous positive airway pressure therapy with excessive daytime sleepiness: a randomized adaptive crossover study. Herring WJ, Liu K, Hutzelmann J, Snavely D, Snyder E, Ceesay P, Lines C, Michelson D, Roth T. Sleep Med; 2013 Oct 01; 14(10):955-63. PubMed ID: 23920422 [Abstract] [Full Text] [Related]
38. Excessive daytime sleepiness in patients suffering from different levels of obstructive sleep apnoea syndrome. Sauter C, Asenbaum S, Popovic R, Bauer H, Lamm C, Klösch G, Zeitlhofer J. J Sleep Res; 2000 Sep 01; 9(3):293-301. PubMed ID: 11012870 [Abstract] [Full Text] [Related]
39. Exenatide improves excessive daytime sleepiness and wakefulness in obese patients with type 2 diabetes without obstructive sleep apnoea. Idris I, Abdulla H, Tilbrook S, Dean R, Ali N. J Sleep Res; 2013 Feb 01; 22(1):70-5. PubMed ID: 22716195 [Abstract] [Full Text] [Related]
40. Comparative efficacy, safety and benefit/risk of alerting agents for excessive daytime sleepiness in patients with obstructive sleep apnoea: a network meta-analysis. Pépin JL, Lehert P, Ben Messaoud R, Joyeux-Faure M, Caussé C, Asin J, Barbé F, Bonsignore MR, Randerath W, Verbraecken J, Craig S, Dauvilliers Y. EClinicalMedicine; 2024 Oct 01; 76():102843. PubMed ID: 39346006 [Abstract] [Full Text] [Related] Page: [Previous] [Next] [New Search]